The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia

Alessia Casolaro, Josee Golay, Clara Albanese, Roberta Ceruti, Veronica Patton, Sabrina Cribioli, Alice Pezzoni, Marco Losa, Gemma Texido, Ursula Giussani, Francesco Marchesi, Nadia Amboldi, Barbara Valsasina, Silvia Bungaro, Gianni Cazzaniga, Alessandro Rambaldi, Martino Introna, Enrico Pesenti, Rachele Alzani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CD56 is expressed in 15-20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+ monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.

Original languageEnglish
Article numbere58424
JournalPLoS One
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 8 2013

Fingerprint

Leukemia, Monocytic, Acute
myeloid leukemia
leukemia
Acute Myeloid Leukemia
phosphotransferases (kinases)
Cytarabine
Neurology
Biomarkers
Tumors
Modulation
therapeutics
Tissue
Survival
new drugs
multiple drug resistance
Multiple Drug Resistance
Therapeutic Uses
NMS P937
polo-like kinase 1
Karyotype

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. / Casolaro, Alessia; Golay, Josee; Albanese, Clara; Ceruti, Roberta; Patton, Veronica; Cribioli, Sabrina; Pezzoni, Alice; Losa, Marco; Texido, Gemma; Giussani, Ursula; Marchesi, Francesco; Amboldi, Nadia; Valsasina, Barbara; Bungaro, Silvia; Cazzaniga, Gianni; Rambaldi, Alessandro; Introna, Martino; Pesenti, Enrico; Alzani, Rachele.

In: PLoS One, Vol. 8, No. 3, e58424, 08.03.2013.

Research output: Contribution to journalArticle

Casolaro, A, Golay, J, Albanese, C, Ceruti, R, Patton, V, Cribioli, S, Pezzoni, A, Losa, M, Texido, G, Giussani, U, Marchesi, F, Amboldi, N, Valsasina, B, Bungaro, S, Cazzaniga, G, Rambaldi, A, Introna, M, Pesenti, E & Alzani, R 2013, 'The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia', PLoS One, vol. 8, no. 3, e58424. https://doi.org/10.1371/journal.pone.0058424
Casolaro, Alessia ; Golay, Josee ; Albanese, Clara ; Ceruti, Roberta ; Patton, Veronica ; Cribioli, Sabrina ; Pezzoni, Alice ; Losa, Marco ; Texido, Gemma ; Giussani, Ursula ; Marchesi, Francesco ; Amboldi, Nadia ; Valsasina, Barbara ; Bungaro, Silvia ; Cazzaniga, Gianni ; Rambaldi, Alessandro ; Introna, Martino ; Pesenti, Enrico ; Alzani, Rachele. / The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. In: PLoS One. 2013 ; Vol. 8, No. 3.
@article{a1b40d67f4fd47bf8ec254ca33912993,
title = "The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia",
abstract = "CD56 is expressed in 15-20{\%} of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+ monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.",
author = "Alessia Casolaro and Josee Golay and Clara Albanese and Roberta Ceruti and Veronica Patton and Sabrina Cribioli and Alice Pezzoni and Marco Losa and Gemma Texido and Ursula Giussani and Francesco Marchesi and Nadia Amboldi and Barbara Valsasina and Silvia Bungaro and Gianni Cazzaniga and Alessandro Rambaldi and Martino Introna and Enrico Pesenti and Rachele Alzani",
year = "2013",
month = "3",
day = "8",
doi = "10.1371/journal.pone.0058424",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia

AU - Casolaro, Alessia

AU - Golay, Josee

AU - Albanese, Clara

AU - Ceruti, Roberta

AU - Patton, Veronica

AU - Cribioli, Sabrina

AU - Pezzoni, Alice

AU - Losa, Marco

AU - Texido, Gemma

AU - Giussani, Ursula

AU - Marchesi, Francesco

AU - Amboldi, Nadia

AU - Valsasina, Barbara

AU - Bungaro, Silvia

AU - Cazzaniga, Gianni

AU - Rambaldi, Alessandro

AU - Introna, Martino

AU - Pesenti, Enrico

AU - Alzani, Rachele

PY - 2013/3/8

Y1 - 2013/3/8

N2 - CD56 is expressed in 15-20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+ monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.

AB - CD56 is expressed in 15-20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+ monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.

UR - http://www.scopus.com/inward/record.url?scp=84874761718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874761718&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0058424

DO - 10.1371/journal.pone.0058424

M3 - Article

C2 - 23520509

AN - SCOPUS:84874761718

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e58424

ER -